CoChat

Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

The gut microbiota is a crucial regulator of anti-tumour immunity during immune checkpoint inhibitor therapy. Several bacteria that promote an anti-tumour response to immune checkpoint inhibitors have been identified in mice 1-6. Moreover, transplantation of faecal specimens from responders can improve the efficacy of anti-PD-1 therapy in patients with melanoma 7,8. However, the increased efficacy from faecal transplants is variable and how gut bacteria promote anti-tumour immunity remains unclear. Here we show that the gut microbiome downregulates PD-L2 expression and its binding partner repulsive guidance molecule b (RGMb) to promote anti-tumour immunity and identify bacterial species that mediate this effect. PD-L1 and PD-L2 share PD-1 as a binding partner, but PD-L2 can also bind RGMb. We demonstrate that blockade of PD-L2-RGMb interactions can overcome microbiome-dependent resistance to PD-1 pathway inhibitors. Antibody-mediated blockade of the PD-L2-RGMb pathway or conditional deletion of RGMb in T cells combined with an anti-PD-1 or anti-PD-L1 antibody promotes anti-tumour responses in multiple mouse tumour models that do not respond to anti-PD-1 or anti-PD-L1 alone (germ-free mice, antibiotic-treated mice and even mice colonized with stool samples from a patient who did not respond to treatment). These studies identify downregulation of the PD-L2-RGMb pathway as a specific mechanism by which the gut microbiota can promote responses to PD-1 checkpoint blockade. The results also define a potentially effective immunological strategy for treating patients who do not respond to PD-1 cancer immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-023-06026-3

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 191

Metadata

Authors
Park, J. S., Gazzaniga, F. S., Wu, M., Luthens, A. K., Gillis, J., Zheng, W., LaFleur, M. W., Johnson, S. B., Morad, G., Park, E. M., Zhou, Y., Watowich, S. S., Wargo, J. A., Freeman, G. J., Kasper, D. L., & Sharpe, A. H.
Affiliations
  • Harvard University (US)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
  • Freeman, Gordon J.
  • Kasper, Dennis L.
  • Sharpe, Arlene H.
Venue
Nature
Published
2023-05-03
Volume
617
Issue
7960
Pages
377-385
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4367848890
Cited by
191
References
37
Citations by year
2026: 39 · 2025: 62 · 2024: 72 · 2023: 18
FWCI
23.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • AstraZeneca
  • GlaxoSmithKline
  • Cancer Prevention and Research Institute of Texas (RP210028)
  • Gilead Sciences
  • Moderna
  • Ipsen
  • National Institutes of Health (RP210028, 1f32ca247072-01)
  • Genentech
  • National Cancer Institute (K22CA258960, P50CA101942, 5F32CA247072-02, F32CA260769, P50CA206963, F32-CA247072)
  • National Institute of Allergy and Infectious Diseases (P01AI056299)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD055148)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
PD-L2, RGMb, gut microbiota, immune checkpoint inhibitors, PD-1 pathway, immunotherapy resistance, antitumor immunity, PD-L1, T cells, melanoma, fecal microbiota transplantation, germ-free mice
MeSH terms
Fecal Microbiota Transplantation, Immune Checkpoint Inhibitors, Animals, Disease Models, Animal, Germ-Free Life, Humans, Immunotherapy, Melanoma, Protein Binding, T-Lymphocytes, Down-Regulation, Cell Adhesion Molecules, Neuronal, Drug Resistance, Neoplasm, Mice, Programmed Cell Death 1 Ligand 2 Protein, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance. https://app.cochat.ai/papers/10.1038/s41586-023-06026-3
The paper
Park, J. S., Gazzaniga, F. S., Wu, M., Luthens, A. K., Gillis, J., Zheng, W., LaFleur, M. W., Johnson, S. B., Morad, G., Park, E. M., Zhou, Y., Watowich, S. S., Wargo, J. A., Freeman, G. J., Kasper, D. L., & Sharpe, A. H. (2023). Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance. Nature. https://doi.org/10.1038/s41586-023-06026-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.